Insider Selling: Annexon, Inc. (NASDAQ:ANNX) CFO Sells $20,183.04 in Stock

Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew sold 6,912 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $2.92, for a total value of $20,183.04. Following the completion of the sale, the chief financial officer now owns 77,770 shares in the company, valued at approximately $227,088.40. This represents a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jennifer Lew also recently made the following trade(s):

• On Thursday, February 13th, Jennifer Lew sold 1,786 shares of Annexon stock. The stock was sold at an average price of $2.98, for a total value of $5,322.28.

Annexon Price Performance

ANNX stock opened at $2.81 on Friday. The business has a fifty day moving average price of $4.26 and a 200 day moving average price of $5.55. Annexon, Inc. has a fifty-two week low of $2.63 and a fifty-two week high of $8.40. The stock has a market capitalization of $299.52 million, a price-to-earnings ratio of -2.68 and a beta of 1.07.

Institutional Trading of Annexon

Several large investors have recently made changes to their positions in ANNX. Parkman Healthcare Partners LLC raised its holdings in shares of Annexon by 0.5% in the third quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock valued at $1,945,000 after buying an additional 1,768 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock valued at $945,000 after acquiring an additional 2,450 shares in the last quarter. GSA Capital Partners LLP increased its position in Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after acquiring an additional 3,355 shares in the last quarter. E Fund Management Co. Ltd. raised its stake in shares of Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Annexon by 6.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after purchasing an additional 4,092 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have issued reports on ANNX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.